Medical Doctor Program year 2021 Source: CMS Open Payments, 2026 publication

James Ziomek

Internal Medicine Los Alamos, NM Medical Doctor

NPI 1487652780 CMS profile 249240

3917 West Rd, Suite 150, Los Alamos, NM 87544

Open in the dashboard

General payments

$14

1 record reported · program year 2021

Research payments

$0

Paid to them · None reported · program year 2021

Ownership & investment interest

$0

None reported

Through program year 2021, James Ziomek of Los Alamos, NM is reported in the CMS Open Payments database as having received $14 across 1 general payment and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 1st percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

1 row
Year Kind Relative to this record's peak year Amount Records
2021 General $14 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • James Ziomek
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to James Ziomek were reported at $0. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year James Ziomek Internal Medicine median Middle half National median
2019 $0 $159 $48–$570 $163
2020 $0 $119 $33–$402 $114
2021 $14 $135 $37–$521 $132
2022 $0 $141 $42–$496 $149
2023 $0 $149 $45–$519 $160
2024 $0 $154 $47–$537 $164
2025 $0 $156 $47–$551 $169

Breakdown

Who paid General payments · program year 2021
  1. Novo Nordisk Inc $14 1 payment

Every payment, record by record

What the payments were for General payments · program year 2021
  1. Food and Beverage $14 1 payment
Products named General payments · program year 2021
  1. RYBELSUS $14 1 payment
  2. Ozempic $14 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 86 drugs

Part D claims

3,266

Median for Internal Medicine: 777

Drug cost

$336,832

Median for Internal Medicine: $73,373

Branded share of claims

20.1%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Mounjaro Tirzepatide Brand 47 $73,387
Eliquis Apixaban Brand 46 $52,788
Dupixent Syringe Dupilumab Brand 11 $40,413
Xarelto Rivaroxaban Brand 39 $32,686
Jardiance Empagliflozin Brand 21 $25,159
Ozempic Semaglutide Brand 19 $17,948
Januvia Sitagliptin Phosphate Brand 12 $17,200
Rybelsus Semaglutide Brand 13 $12,516
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 16 $9,776
Symbicort Budesonide/Formoterol Fumarate Brand 13 $7,014

The 10 drugs with the highest cost, of 86 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 40 billing codes

Paid by Medicare

$187,046

Of which drugs: $21,652

Medicare patients

628

Average age 75

Services billed

7,590

283 women, 345 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 65%
Arthritis 43%
Diabetes 24%
Ischemic heart disease 19%
Chronic kidney disease 16%
Osteoporosis 16%
Cancer 14%
Atrial fibrillation 11%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, denosumab, 1 mg J0897 Office 12 900 $13,996
Injection, methylprednisolone acetate, 1 mg J1010 Office 11 520 $54

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

1 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in New Mexico

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2021

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record